Nidlegy (darleukin/fibromun)

News alerts, weekly reports and conference planners

Company:

Philogen, Sun Pharma

Drug class:

T-cell stimulant, IL-2R agonist, TNF stimulant

Related drugs:

‹

›

Neoadjuvant L19IL2/L19TNF- Pivotal Study (clinicaltrials.gov)

P3, N=214, Recruiting, Philogen S.p.A. | Trial primary completion date: Dec 2023 --> Oct 2024

1 month ago

Trial primary completion date • Surgery

BRAF (B-raf proto-oncogene)

Nidlegy (darleukin/fibromun) • darleukin (L19IL2)

2ms

INTACT/MeRCI: Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients (clinicaltrials.gov)

P2, N=162, Active, not recruiting, Philogen S.p.A.

2 months ago

New P2 trial

Keytruda (pembrolizumab) • Nidlegy (darleukin/fibromun)

7ms

DUNCAN: Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients (clinicaltrials.gov)

P2, N=40, Recruiting, Philogen S.p.A. | Trial completion date: Feb 2023 --> Sep 2024 | Trial primary completion date: Nov 2022 --> Sep 2024

7 months ago

Trial completion date • Trial primary completion date

Nidlegy (darleukin/fibromun)

12ms

KEYNOTE PRESENTATION: Antibody-Cytokine Fusions for the Treatment of Difficult-to-Cure Cancer Types: Emerging Clinical Results (PEGS 2023)

In addition, results from clinical trials with Nidlegy in high-risk basal cell carcinoma patients, candidates for disfiguring surgery who experienced durable complete responses, will be shared. Other clinical trial results in “difficult-to-treat tumors” will be discussed.

12 months ago

Clinical

Nidlegy (darleukin/fibromun)

2years

Neoadjuvant L19IL2/L19TNF- Pivotal Study (clinicaltrials.gov)

P3, N=214, Recruiting, Philogen S.p.A. | Trial primary completion date: Dec 2018 --> Dec 2023

2 years ago

Trial primary completion date

BRAF (B-raf proto-oncogene)

Nidlegy (darleukin/fibromun) • darleukin (L19IL2)

almost3years

Current status of intralesional agents in treatment of malignant melanoma. (PubMed, Ann Transl Med)

This review focuses on the current status of IT agents currently under clinical trials in melanoma. Reviewed therapies include T-VEC, T-VEC with immune checkpoint inhibitors including ipilimumab and pembrolizumab or other agents, RP1, OrienX010, Canerpaturev (C-REV, HF10), CAVATAK (coxsackievirus A21, CVA21) alone or in combination with checkpoint inhibitors, oncolytic polio/rhinovirus recombinant (PVSRIPO), MAGE-A3-expressing MG1 Maraba virus, VSV-IFNbetaTYRP1, suicide gene therapy, ONCOS-102, OBP-301 (Telomelysin), Stimulation of Interferon Genes Pathway (STING agonists) including DMXAA, MIW815 (ADU-S100) and MK-1454, PV-10, toll-like receptors (TLRs) agonists including TLR-9 agonists (SD-101, CMP-001, IMO-2125 or tilsotolimod, AST-008 or cavrotolimod, MGN1703 or lefitolimod), CV8102, NKTR-262 plus NKTR-214, LHC165, G100, intralesional interleukin-2, Daromun (L19IL2 plus L19TNF), Hiltonol (poly-ICLC), electroporation including calcium electroporation and plasmid interleukin-12 electroporation (pIL-12 EP), IT ipilimumab, INT230-6 (cisplatin and vinblastine with an amphiphilic penetration enhancer), TTI-621 (SIRPαFc), CD-40 agonistic antibodies (ABBV-927 and APX005M), antimicrobial peptide LL37 and other miscellaneous agents.

almost 3 years ago

Review • Journal

TYRP1 (Tyrosinase Related Protein 1) • CD40 (CD40 Molecule) • MAGEA3 (MAGE Family Member A3)

Keytruda (pembrolizumab) • Yervoy (ipilimumab) • Imlygic (talimogene laherparepvec) • bempegaldesleukin (NKTR-214) • vidutolimod (CMP-001) • Fibromun (onfekafusp alfa) • ONCOS-102 • cavrotolimod (AST-008) • cisplatin/vinblastine/SHAO-FA (INT230-6) • nelitolimod (SD-101) • ADU-S100 • CV8102 • Cavatak (gebasaxturev) • Hiltonol (poly-ICLC) • LHC165 • NKTR-262 • Nidlegy (darleukin/fibromun) • OrienX010 • Telomelysin (suratadenoturev) • canerpaturev (TBI-1401) • giloralimab (ABBV-927) • lefitolimod (MGN1703) • sotigalimab (PYX-107) • tilsotolimod (IMO-2125) • ulevostinag (MK-1454)